Bal Pharma Board Approves Unaudited Results, JV Investment, Director Changes

Bal Pharma Ltd's Board of Directors met on August 12, 2026, approving unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also approved a change in designation for two directors, effective October 1, 2026, subject to member approval. Additionally, an investment of up to ₹9 Crores in a proposed Joint Venture entity in the Philippines was approved. The company also approved the allotment of 10,00,000 warrants to a promoter for ₹8.40 Crores, with 25% of the issue price already received.